Luminal breast cancers, which represent the largest proportion of all breast tumors (∼70–75%) and have a more favorable prognosis compared to the other molecular subtypes, benefit from the use of targeted endocrine therapies due to the expression of hormone receptors. This evidence concerns the gene NR4A1 and breast carcinoma.